Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0634 in Postmenopausal Women With Overactive Bladder
NCT00231790Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0634 in overactive bladder (OAB) (4 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in the number of micturitions per day averaged over a diary card week at 8 weeks. Started Aug 2005; status: completed.
02
Drugs
MK-0634
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00231790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231790.